Drug intelligence / Profile preview

RQ3025 (Walvax Biotechnology Co., Ltd.)

Development stage: Unknown
Lead developer: Walvax Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RQ3025 is a bivalent mRNA-based vaccine developed for the prevention of COVID-19. It is designed to provide broad protection against SARS-CoV-2 by targeting the spike proteins of multiple variants, specifically the Alpha/Beta strains and the Omicron BA.2/4/5 subvariants. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver mRNA encoding the viral antigens, stimulating both humoral and cellular immune responses. It has been evaluated as a booster dose in individuals previously vaccinated with other COVID-19 vaccines to enhance neutralizing antibody levels against circulating variants.

Other names: Alpha/Beta+Omicron BA.2/4/5 bivalent mRNA vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on RQ3025 (Walvax Biotechnology Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ3025 (Walvax Biotechnology Co., Ltd.).

Explore the full profile